ArticleScientific reports2025
UDP-glycosyltransferases alleviate the toxic effects of deoxynivalenol on the growth performance and gut damage of Kunming mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to assess the effects of UDP-glycosyltransferases (UGTs) on alleviating the toxic effects of deoxynivalenol (DON) on Kunming mouse growth performance and gut damage. In this study, a total of 60 3-week-old male Kunming mice were randomly divided into 4 groups and fed the following dietary and drug treatments for 7 weeks: CON, basal diet; CTX, basal diet with i.p. injection of cyclophosphamide (CTX); CTX + DON, basal diet with 12 mg/kg DON and i.p. injection of cyclophosphamide; and CTX + DON + UGTs, basal diet with 12 mg/kg DON and UGTs 1 mg/kg and i.p. injection of cyclophosphamide. Compared with those in the CON group, the growth performance, serum immunoglobulin contents (IgG), antioxidant defense enzyme activities(SOD), intestinal barrier integrity and permeability (the ratio of villi length to crypt depth), tight junction proteins (occludin and claudin 5) expression, intestinal cell apoptosis (Bcl-2), and histopathological lesions in the guts of the DON- and CTX-treated mice were significantly lower (p < 0.05). These negative effects on DON-exposed mice were significantly mitigated when the mice received a UGT-supplemented diet (1 mg/kg) (p < 0.05). We concluded that UGTs could serve as dietary supplements to treat intestinal disorders associated with DON-induced growth-retardation in animals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.